ArticleFrontiers in cellular and infection microbiology2021
Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients.
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- The composition alteration of gut microbiota in lung cancer: a systematic review and meta-analysis.Frontiers in microbiology · 2026Pooled it
- Metabolomics and metabolites in cancer diagnosis and treatment.Molecular biomedicine · 2025Pooled it
- ACE inhibitory casein peptide lowers blood pressure and reshapes gut microbiota in a randomized double blind placebo controlled trial.Scientific reports · 2025Trial
- The impact of gut microbiota and metabolite-driven immune cell spatiotemporal dynamics on tumors.Gut microbes · 2026Review
- Integrated metagenomic and metabolomic analysis identifies severity-specific inflammatory and metabolic signatures in post-stroke depression.Gut microbes · 2026Article
- Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications.Cancer medicine · 2026Review
- Integration of blood protein-metabolic profiles via machine learning to enable the accurate early detection of non-small cell lung cancer.Respiratory research · 2026Article
- The Dynamic Gut Microbiota: Monitoring Alterations During Lung Cancer Progression for Diagnosis and Precision Medicine.International journal of molecular sciences · 2026Review
- Evaluation of the ALIBIRD mHealth Platform for Care of Patients With Lung Cancer: Prospective Pilot Study.JMIR cancer · 2026Article
- Oral microbiome-metabolome axis links glycerophospholipid dysregulation to Alzheimer's disease.Journal of oral microbiology · 2026Article
- Gut-Lung Microbiota Axis Shapes the Immune Microenvironment and Immunotherapeutic Response in Lung Cancer.International journal of biological sciences · 2026Review
- High-dose folic acid therapy ameliorates gut microbiota dysbiosis in reproductive-aged women with hyperhomocysteinemia.Frontiers in nutrition · 2026Article
- Serum Untargeted Metabolomics Profiling of Esophageal Squamous Cell Carcinoma in High-Incidence Areas of China.International journal of general medicine · 2026Article
- Lysophosphatidylethanolamine (LysoPE) in health and disease: a narrative review of its pathophysiological mechanisms and translational potential as a biomarker.Frontiers in cell and developmental biology · 2026Review
- The gut microbiota as a potential biomarker in patients with EGFR-mutant lung cancer.Scientific reports · 2025Article
- Integrated analysis of gut microbiota, fecal and serum metabolites in type 2 diabetes mellitus with peripheral neuropathy.Journal of endocrinological investigation · 2025Article
- Biomarkers for non-small cell lung cancer risk using multi-omics approaches: a nested case-control study.Translational lung cancer research · 2025Article
- Untargeted metabolomics analysis of metabolite changes in gastric cancer patients from plateau regions.World journal of gastrointestinal oncology · 2025Article
- Characteristics of gut and lung microbiota in patients with lung masses and their relationship with clinical features.BMC microbiology · 2025Article
- Characterisation of the Faecal Microbiota in Dogs with Mast Cell Tumours Compared with Healthy Dogs.Animals : an open access journal from MDPI · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer (LC) is one of the most aggressive, prevalent and fatal malignancies. Gut microbes and their associated metabolites are thought to cause and modulate LC development, albeit influenced by the host genetic make-up and environment. Herein, we identified and classified gut microbiota and serum metabolites associated with LC. Methods: Stool samples were collected from 41 LC patients and 40 healthy volunteers. The gut microbiota was analyzed using 16S rRNA gene sequencing. Serum samples were collected from the same LC patients (n=30) and healthy volunteers (n=30) and serum metabolites were analyzed using liquid chromatography-mass spectrometry (LC-MS). Microbiome and metabolome data were analyzed separately and integrated for combined analysis using various bioinformatics methods. Results: Serum metabolomics uncovered 870 metabolites regulated in 76 metabolic pathways in both groups. Microbial diversity analyses identified 15967 operational taxonomic units (OTUs) in groups. Of these, the abundance of 232 OTUs was significantly different between HC and LC groups. Also, serum levels of glycerophospholipids (LysoPE 18:3, LysoPC 14:0, LysoPC 18:3), Imidazopyrimidines (Hypoxanthine), AcylGlcADG 66:18; AcylGlcADG (22:6/22:6/22:6) and Acylcarnitine 11:0 were substantially different between HC and LC groups. Combined analysis correlated LC-associated microbes with metabolites, such as Erysipelotrichaceae_UCG_003, Clostridium and Synergistes with glycerophospholipids. Conclusions: There is an intricate relationship between gut microbiome and levels of several metabolites such as glycerophospholipids and imidazopyrimidines. Microbial-associated metabolites are potential diagnostic biomarkers and therapeutic targets for LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.